PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Mood disorder

Drugs in development · updated 30 October 2026

Mood disorder: drugs in development

As of 30 October 2026 there are 11 active clinical trials (recruiting or ongoing, phases I–III) on 8 drugs for mood disorder. 6 are experimental, that is not yet approved in the United States.

11Active trials
6Experimental drugs
1Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
BrenipatideIII2NCT07775300
PsilocybinPsilocybineII2NCT06943573
SPT-300II2NCT07161700
BMS-986511II1NCT07772531
HydroxynorketamineII1NCT06511908
MelatoninSlenyto®, Circadin®II1NCT07472075

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
CannabidiolEpidiolex, Epidyolex®III1NCT05867849
Nitrous OxideNitrous Oxide, Usp®I1NCT03736538

Sorted by most advanced phase and number of active trials.

All 8 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Specific forms

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D019964 “Mood Disorders”.

ItalianoFrançaisDeutsch